Statin use and survival outcomes in colorectal cancer patients with hepatic steatosis evaluated by fatty liver index: a nationwide cohort study
Precision and Future Medicine · 30.06.2026 · 10 (2) · 63-76
DOI: 10.23838/pfm.2026.00065 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Precision and Future Medicine, erschienen am 30.06.2026. Verfasst von So Hee Lee und 4 weiteren Autor:innen. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: SilverLining-Medical Co., Ltd., National Research Foundation of Korea, Korea Health Industry Development Institute.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
Hepatic steatosis influences the hepatic microenvironment, thereby affecting the prognosis of colorectal cancer (CRC). This study aimed to evaluate whether pre-existing hepatic steatosis is associated with survival outcomes in patients with CRC and whether statin use after CRC diagnosis is associated with improved survival in patients with hepatic steatosis.
Methods
A nationwide retrospective cohort study was conducted using data from the Korea- Clinical data Utilization network for Research Excellence (K-CURE) Cancer Public Library from 2012 to 2021. Newly diagnosed patients with CRC aged 40 to 80 years with localized or regional disease were included. Hepatic steatosis was defined as a fatty liver index ≥60. The primary analysis evaluated the association between hepatic steatosis, CRC, and all-cause mortality. Secondary analysis was restricted to patients with hepatic steatosis, and statin users and non-users were compared using an active-comparator design. Cox proportional hazards models, Fine–Gray competing risk models, and propensity score matching were applied.
Results
In 57,368 patients with CRC, hepatic steatosis was associated with an increased risk of CRC-specific mortality and all-cause mortality. After propensity score matching, the adjusted hazard ratios (aHR) for CRC-specific mortality were 1.283 (95% confidence interval [CI], 1.055 to 1.561) and 1.171 (95% CI, 1.001 to 1.371) for all-cause mortality. In a secondary analysis of patients with hepatic steatosis, statin use after CRC diagnosis was associated with a reduced risk of CRC-specific mortality (aHR, 0.462; 95% CI, 0.232 to 0.920) and all-cause mortality (aHR, 0.504; 95% CI, 0.290 to 0.877).
Conclusion
Pre-existing hepatic steatosis is associated with poor survival in patients with CRC. In patients with hepatic steatosis, statin use after CRC diagnosis was associated with improved cancer-specific and overall survival. These findings suggest that hepatic steatosis may be a clinically relevant prognostic factor in CRC and that statins may have potential survival benefits in this subgroup.
Förderung
- SilverLining-Medical Co., Ltd.
- National Research Foundation of Korea
- Korea Health Industry Development Institute
- Ministry of Health and Welfare
- Ajou University School of Medicine
Zitieren
APA
Lee, S. H., An, M. H., Kim, M., Kim, H., & Park, S. S. (2026). Statin use and survival outcomes in colorectal cancer patients with hepatic steatosis evaluated by fatty liver index: a nationwide cohort study. Precision and Future Medicine, 10(2), 63-76. https://doi.org/10.23838/pfm.2026.00065
Vancouver
Lee SH, An MH, Kim M, Kim H, Park SS. Statin use and survival outcomes in colorectal cancer patients with hepatic steatosis evaluated by fatty liver index: a nationwide cohort study. Precision and Future Medicine. 2026;10(2):63-76. doi:10.23838/pfm.2026.00065
BibTeX
@article{Lee2026,
author = {Lee, So Hee and An, Min Ho and Kim, Min-Gyu and Kim, Hanki and Park, Soon Sang},
title = {Statin use and survival outcomes in colorectal cancer patients with hepatic steatosis evaluated by fatty liver index: a nationwide cohort study},
journal = {Precision and Future Medicine},
year = {2026},
volume = {10},
number = {2},
pages = {63--76},
doi = {10.23838/pfm.2026.00065}
}
EUVIMED